Merck


MRK 0.85%

& Co. will help produce

Johnson & Johnson’s


JNJ 0.40%

single-dose Covid-19 vaccine, President Biden plans to announce on Tuesday, as the administration pushes to get the shot to the American public at a faster pace.

The president is expected to make the announcement while giving an update on the pandemic, administration officials said. The assistance from Merck, a competitor to Johnson & Johnson, will help speed up production after the one-shot vaccine was authorized by the Food and Drug Administration on Saturday.

J&J declined to comment. In a statement on Tuesday, a Merck spokesman said the company “remains steadfast in our commitment to contribute to the global response to the pandemic and to preparing to address future pandemics.”

U.S. regulators cleared J&J’s vaccine—the third to receive approval—for use, but initial supplies are limited as the company boosts manufacturing efforts. The New Brunswick, N.J.-based company had made nearly four million doses for initial shipments that began going out this week. The Biden administration said it expected about 20 million doses to be delivered by the end of March.

The Biden administration has said it expects to have enough doses for all Americans by the end of July, based on agreements to purchase the vaccine from

Pfizer Inc.

and

Moderna Inc.

It wasn’t immediately clear how the J&J vaccine would affect that timetable.

Merck, a Kenilworth, N.J. firm, is a pioneer in vaccines, such as those to prevent mumps and shingles, but has been on the sidelines of the Covid-19 vaccine race since scrapping two programs in January after disappointing clinical studies. Merck was also slower to pursue Covid-19 vaccines, The Wall Street Journal reported last year.

The government expects about 20 million doses of the J&J vaccine to be delivered by the end of March.



Photo:

johnson & johnson/Reuters

The partnership between J&J and Merck would mark the latest example of pharmaceutical rivals working together to make Covid-19 vaccines.

Sanofi SA

and

Novartis AG

are helping to make the shot from Pfizer Inc. and

BioNTech SE.

The partnership comes as Mr. Biden’s administration has emphasized the urgency of vaccinating the public against Covid-19 and warned of a new and more transmissible variant that is rapidly spreading across the country.

White House Covid-19 coordinator Jeff Zients said on Monday that the administration had begun distributing 3.9 million doses of the J&J vaccine to states, tribes and territories, as well as to pharmacies and community health centers. Mr. Zients said the company had communicated to the administration that supply “will be limited for the next couple of weeks” after the initial distribution but expected to deliver additional doses by the end of March.

A panel of medical experts on Friday endorsed the Johnson & Johnson single-dose Covid-19 vaccine for emergency use, paving the way for the Food and Drug Administration to authorize the shot. Photo: Johnson & Johnson/Handout (Originally published Feb. 26, 2021)

Write to Sabrina Siddiqui at [email protected] and Tarini Parti at [email protected]

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8



Source link

By EDONS